BRISBANE, Calif., May 15 BiPar Sciences, Inc., a privatelyheld biopharmaceutical company developing novel cancer therapies, todayannounced that data supporting its lead PARP inhibitor, BSI-201, will bepresented at the 2008 American Society of Clinical Oncology annual meeting inChicago.
Findings will be presented from the first in human Phase 1 study ofBSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as amonotherapy in subjects with advanced solid tumors. BiPar will also present aPhase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine,temozolomide and carboplatin/paclitaxel in subjects with advanced solidtumors. The primary objective of these respective studies is to assess thesafety profile of BSI-201 when used as a monotherapy and in combination withcytotoxic chemotherapy in subjects with measurable disease.
About BiPar Sciences
BiPar Sciences is a drug development company with a therapeutic focus onexploring novel mechanisms of action in oncology. The lead development programis based on DNA repair, specifically with poly ADP-ribose polymerase (PARP)inhibitors. The lead product within that program is BSI-201, a platform drugwith the potential to be a superior new treatment across a range of tumortypes, both as monotherapy and in combination with chemotherapy. The companyis currently testing BSI-201 in a range of Phase 2 trials in breast, brain andovarian cancer.The schedule of poster presentations is as follows: Title: First in Human Phase 1 Study of BSI-201, a Small Molecule Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with Advanced Solid Tumors When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session Abstract#: 3577 Title: A Phase 1B Study Evaluating BSI-201 in Combination with Chemotherapy in Subjects with Advanced Solid Tumors When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session Abstract #: 3579
SOURCE BiPar Sciences, Inc.